Hormonal
Initiation of GLP-1 receptor agonists in adults with obesity or type 2 diabetes is associated with a substantially reduced risk of all-cause mortality, with the survival benefit being more pronounced in patients under 65 years of age and those with cardiometabolic comorbidities.
If you have obesity or type 2 diabetes, starting a GLP-1 RA (like semaglutide or liraglutide) is strongly associated with living longer, especially if you are under 65 or have other heart/kidney risks. While there is a small, early risk of pancreatitis, the survival benefit is substantial. Discuss this risk-benefit profile with your doctor, particularly if you have a history of pancreatic issues.
After PSM, GLP-1 RA use was associated with a substantially lower risk of all-cause death (HR 0.554, 95% CI 0.542–0.566)... The survival benefit was more pronounced in younger people and those with cardiometabolic comorbidities
Why this rating
Large-scale retrospective observational study (TriNetX) with propensity score matching, but subject to residual confounding and healthy-user bias.
Source
Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network
Enrico Tartaglia et al. · Cardiovascular Diabetology · 2025
DOI 10.1186/s12933-025-02986-0
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →